Diurnal Group (LON:DNL) posted its quarterly earnings results on Monday. The company reported GBX (12.70) (($0.18)) EPS for the quarter, Bloomberg Earnings reports.

Diurnal Group (LON:DNL) traded down GBX 12.50 ($0.17) during mid-day trading on Wednesday, reaching GBX 201.50 ($2.78). 11,715 shares of the company traded hands, compared to its average volume of 5,226. The stock has a market cap of $185.23 and a P/E ratio of -1,007.50. Diurnal Group has a 52 week low of GBX 118 ($1.63) and a 52 week high of GBX 215.80 ($2.98).

How to Become a New Pot Stock Millionaire

Separately, Numis Securities reaffirmed a “buy” rating and issued a GBX 185 ($2.56) price target on shares of Diurnal Group in a research note on Tuesday, February 13th.

In related news, insider John Goddard purchased 10,791 shares of Diurnal Group stock in a transaction that occurred on Friday, January 5th. The shares were bought at an average price of GBX 540 ($7.46) per share, with a total value of £58,271.40 ($80,507.60).

ILLEGAL ACTIVITY WARNING: “Diurnal Group (DNL) Posts Quarterly Earnings Results” was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.dailypolitical.com/2018/03/14/diurnal-group-dnl-posts-quarterly-earnings-results-2.html.

Diurnal Group Company Profile

Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.

Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.